Phase 3 Recruiting NIH
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Novant Health Presbyterian Medical Center — Charlotte, North Carolina
- Atrium Health Cabarrus/LCI-Concord — Concord, North Carolina
- Duke University Medical Center — Durham, North Carolina
Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in North Carolina: - Research Site — Charlotte, North Carolina
- Research Site — Wilmington, North Carolina
- Research Site — Winston-Salem, North Carolina
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in North Carolina: - Southeastern Medical Oncology Center-Clinton — Clinton, North Carolina
- Southeastern Medical Oncology Center-Goldsboro — Goldsboro, North Carolina
- Southeastern Medical Oncology Center-Jacksonville — Jacksonville, North Carolina
Phase 2 Recruiting NIH
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Atrium Health Cabarrus/LCI-Concord — Concord, North Carolina
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
Phase 2 Recruiting Academic/Other
The purpose of this research study is to determine the safety and efficacy of administering two doses of lerapolturev in residual disease (within tumor margins) after surgery, followed later by repeated injections of lerapolturev in the su…
Sponsor: Darell Bigner
NCT ID: NCT06177964
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 2 Recruiting Academic/Other
This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell death protein 1) or PD-L1 (programmed death-ligand 1) inhibitor treatment who have …
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT07630168
Sites in North Carolina: - University of North Carolina at Chapel Hill, Department of Radiation Oncology — Chapel Hill, North Carolina
Phase 2 Recruiting Academic/Other
This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or intoleranc…
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT04375384
Sites in North Carolina: - Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
Phase 2 Recruiting Academic/Other
Radiation therapy is an essential treatment for tumors in the chest area, including breast, lung, esophageal, mediastinal cancers, and spine metastases. Although technical advances have reduced treatment-related illness and death, radiatio…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT07685938
Sites in North Carolina: - Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill — Chapel Hill, North Carolina
Phase 2 Recruiting Academic/Other
The goal of this trial is to learn if adding consolidative chemotherapy to routine chemoradiation can better control both local recurrence and metastasis and reduce the need for surgical intervention.
Sponsor: Duke University
NCT ID: NCT07603375
Sites in North Carolina: - Duke University Medical Center — Durham, North Carolina
Phase 1 Recruiting Industry
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies
Sponsor: AstraZeneca
NCT ID: NCT05877599
Sites in North Carolina: - Research Site — Charlotte, North Carolina
- Research Site — Winston-Salem, North Carolina
Phase 1 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat adva…
Sponsor: AbbVie
NCT ID: NCT06084481
Sites in North Carolina: - Duke Cancer Center /ID# 255129 — Durham, North Carolina
Phase 1 Recruiting Industry
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumo…
Sponsor: Exelixis
NCT ID: NCT06545331
Sites in North Carolina: - Carolina BioOncology Institute — Huntersville, North Carolina
Phase 1 Recruiting Industry
The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligib…
Sponsor: EvolveImmune United, Inc
NCT ID: NCT07217171
Sites in North Carolina: - Duke University Medical Center - Duke Cancer Center — Durham, North Carolina
Phase 1 Recruiting Industry
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driv…
Sponsor: Bicara Therapeutics
NCT ID: NCT04429542
Sites in North Carolina: - Levine Cancer Institute — Charlotte, North Carolina
Phase 1 Recruiting Industry
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
Sponsor: Dren Bio
NCT ID: NCT06999187
Sites in North Carolina: - Dren Investigational Site — Huntersville, North Carolina
Phase 1 Recruiting Industry
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT05107674
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
Phase 1 Recruiting Industry
This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for part…
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT07219212
Sites in North Carolina: - University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
Phase 1 Recruiting Industry
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid …
Sponsor: Plexium, Inc.
NCT ID: NCT07284186
Sites in North Carolina: - Research Site — Durham, North Carolina
Phase 1 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy and in comb…
Sponsor: AbbVie
NCT ID: NCT07241039
Sites in North Carolina: - Carolina BioOncology Institute /ID# 272380 — Huntersville, North Carolina
Phase 1 Recruiting Industry
In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection. The primary objective will be to estab…
Sponsor: Immunolight, LLC
NCT ID: NCT04389281
Sites in North Carolina: - Levine Cancer Institute — Charlotte, North Carolina
- Duke University — Durham, North Carolina
Phase 1 Recruiting Industry
This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of …
Sponsor: Memgen, Inc.
NCT ID: NCT05076760
Sites in North Carolina: - Duke Cancer Institute — Durham, North Carolina
Phase 1 Recruiting Academic/Other
This pilot feasibility study evaluates the use of a hyaluronic acid-based spacing gel (Barrigel) in participants with cervical cancer undergoing chemoradiotherapy (chemoRT), including brachytherapy, as part of standard care. The primary go…
Sponsor: UNC Lineberger Comprehensive Cancer Center
NCT ID: NCT07292818
Sites in North Carolina: - Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill — Chapel Hill, North Carolina